Treatment-resistant schizophrenia — TRRIP and clozapine pathway (MEQ)

(i) Critique of the TRS label / pseudo-resistance. This is not established true TRS. Olanzapine 5 mg for 10 days is inadequate dose and duration; risperidone 2 mg for 3 weeks is incomplete; quetiapine 25 mg is a sleep dose, not an antipsychotic efficacy trial; adherence is clearly doubtful; heavy cannabis continues. TRS requires failure of adequate trials after pseudo-resistance exclusion.[1][6]

(ii) Reassessment priorities. Risk: suicide, violence (paranoia-driven), self-neglect, vulnerability; means, intent, plan, protective factors. Substance formulation and harm reduction. Medical/organic exclusion (baseline bloods, consider further tests if red flags). MSE for catatonia and command hallucinations. Collateral and capacity. Treatment history reconstruction with adherence method. Least-restrictive legal pathway if needed (jurisdiction-specific statutes — do not invent section numbers).[4]

(iii) Adequate trial and LAI plan. Adequate trial = therapeutic dose for about 6 weeks at that dose, verified adherence, measured outcome, substances addressed. Because oral adherence is doubtful, offer an LAI of a previously partially helpful or preferred agent with documented initiation/overlap rules to prove exposure before the TRS stamp. Serial CGI/symptom tracking and cannabis reduction plan run in parallel. Do not call failure after days at low dose.[1][5][6]

(iv) TRRIP and clozapine offer. TRRIP: confirmed schizophrenia-spectrum diagnosis; clinically significant ongoing symptoms; inadequate response to ≥2 different antipsychotics of adequate dose and duration with adherence confirmed; pseudo-resistance excluded.[1] Offer clozapine when criteria are met and monitoring is real: baseline FBC/ANC, ECG, metabolic panel, bowel plan, smoking status, slow titration, no bloods no drug, early myocarditis vigilance, constipation prevention, plasma level teaching threshold (~350 ng/mL) before declaring failure. Kane established clozapine superiority in defined TRS.[2][4][6]

(v) Ultra-TRS. If later clozapine fails, first prove adequacy (dose, duration, plasma level, adherence), re-check diagnosis/substances/organic, then consider clozapine augmentation with evidence-quality caution and ECT augmentation (Petrides randomised evidence) for persistent positives, plus intensive psychosocial care. Nihilism is not a plan.[3][6]